TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B Turnover 31.15%
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+25.95%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.16B
AUM Growth
+$665M
Cap. Flow
-$4.87M
Cap. Flow %
-0.12%
Top 10 Hldgs %
57.45%
Holding
61
New
12
Increased
2
Reduced
9
Closed
7
Avg Time Held
1 year
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
1.3 years

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$121M
2
AURA icon
Aura Biosciences
AURA
+$68.2M
3
TRAX icon
First Tracks Biotherapeutics
TRAX
+$54.1M
4
AVTX icon
Avalo Therapeutics
AVTX
+$36M
5
EDIT icon
Editas Medicine
EDIT
+$32.5M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$170M
2
ABVX icon
Abivax
ABVX
+$53.6M
3
FULC icon
Fulcrum Therapeutics
FULC
+$40.3M
4
TNGX icon
Tango Therapeutics
TNGX
+$35.8M
5
RVMD icon
Revolution Medicines
RVMD
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Financials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LONA icon
51
LeonaBio Inc
LONA
$50.8M
$4.27M 0.1%
464,398
– –
2025 Q4
2 quarters
JATT icon
52
JATT II Acquisition Corp
JATT
$80.9M
$2.27M 0.05%
+200,000
New +$2.13M
2026 Q2
0 quarters
CNTX icon
53
Context Therapeutics
CNTX
$23.5M
$1.49M 0.04%
2,682,696
– –
2026 Q1
1 quarter
EIKN icon
54
Eikon Therapeutics
EIKN
$380M
$495K 0.01%
+37,902
New +$387K
2026 Q2
0 quarters
CNTA
55
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-4,286,480
Closed -$170M –
FULC icon
56
Fulcrum Therapeutics
FULC
$280M
– –
-5,250,000
Closed -$40.3M –
GPCR icon
57
Structure Therapeutics
GPCR
$1.56B
– –
-140,411
Closed -$6.77M –
LQDA icon
58
Liquidia Corp
LQDA
$3.04B
– –
-403,048
Closed -$15.2M –
URGN icon
59
UroGen Pharma
URGN
$1.79B
– –
-405,365
Closed -$7.29M –
VTGN icon
60
VistaGen Therapeutics
VTGN
$9.17M
– –
-2,676,580
Closed -$1.53M –
UPB icon
61
Upstream Bio Inc
UPB
$187M
– –
-181,063
Closed -$1.63M –
1 2
3

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return
CCMIC
Cardinal Capital Management Inc (Canada) Winnipeg, Manitoba, Canada $4.13B AUM 31.23% 1-Year Est. Return

TCG Crossover Management's Q2 2026 Portfolio in Review

As of Q2 2026, TCG Crossover Management held 61 positions worth $4.16B, up 19% from $3.5B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

TCG Crossover Management's Q2 2026 filing shows 12 new, 2 increased, 9 reduced and 7 closed positions. Its largest new stake was Zai Lab: 6,137,627 shares worth $117M. The largest sale was Centessa Pharmaceuticals, an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • TCG Crossover Management's largest Q2 2026 buy was Zai Lab: 6,137,627 shares worth $117M.
  • TCG Crossover Management added most to Avalo Therapeutics in Q2 2026, an estimated $36M increase.
  • TCG Crossover Management's biggest Q2 2026 reduction was Abivax, cutting an estimated $53.6M.
  • TCG Crossover Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $170M.
  • TCG Crossover Management's ten largest holdings make up 57% of its $4.16B portfolio in Q2 2026.
  • TCG Crossover Management opened 12 new positions and closed 7 in Q2 2026.
  • TCG Crossover Management's portfolio value rose 19% quarter-over-quarter to $4.16B.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.